Naltrexone And Bupropion
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders
Orexigen Therapeutics, Inc · Phase 2/3 · Completed · Enrollment 3
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Naltrexone/Bupropion | Obesity or overweight | n/r | n/r | n/r | n/r |
| Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |